Human RCTPubMed ID: 38531847·2024

Retatrutide Effects on Appetite-Regulating Hormones: Ghrelin, Peptide YY, and Cholecystokinin

Astrup A, Madsbad S, Mesch VR, et al.

The American Journal of Clinical Nutrition, 2024 · n = 143

Key finding

Retatrutide reduced fasting ghrelin by 32% vs 2% placebo; increased fasting PYY by 48% vs 12% placebo; changes in hormone levels correlated weakly (r=0.15) with weight loss.

Summary

Hormonal analysis substudy measuring fasting and postprandial levels of ghrelin, PYY, CCK, leptin, and adiponectin throughout the retatrutide trial.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

RetatrutideL4

A triple-acting GIP/GLP-1/glucagon receptor agonist in Phase 3 trials showing potentially the highest weight loss of any drug in development.

More research on Retatrutide

TRIUMPH-NAS: Retatrutide for Non-Alcoholic Steatohepatitis

Journal of Hepatology · 2025 · Human RCT

TRIUMPH-OA: Retatrutide for Obesity-Related Osteoarthritis

Osteoarthritis and Cartilage · 2025 · Human RCT

Genetic Polymorphisms Predict Retatrutide Response: GWAS Analysis

Cell Metabolism · 2025 · Human RCT

Comparative Efficacy: Retatrutide vs Tirzepatide in Randomized Head-to-Head Trial

New England Journal of Medicine · 2025 · Human RCT

TRIUMPH 1: Retatrutide versus Placebo in Obesity (Phase 3)

Lancet Diabetes & Endocrinology · 2024 · Human RCT